227 related articles for article (PubMed ID: 22562469)
21. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA
Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
[TBL] [Abstract][Full Text] [Related]
22.
Kuttel MM; Casadevall A; Oscarson S
Molecules; 2020 Jun; 25(11):. PubMed ID: 32517333
[TBL] [Abstract][Full Text] [Related]
23. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
24. Contribution of the mannan backbone of cryptococcal glucuronoxylomannan and a glycolytic enzyme of Staphylococcus aureus to contact-mediated killing of Cryptococcus neoformans.
Ikeda R; Saito F; Matsuo M; Kurokawa K; Sekimizu K; Yamaguchi M; Kawamoto S
J Bacteriol; 2007 Jul; 189(13):4815-26. PubMed ID: 17483230
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
[TBL] [Abstract][Full Text] [Related]
26. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.
Cherniak R; Morris LC; Belay T; Spitzer ED; Casadevall A
Infect Immun; 1995 May; 63(5):1899-905. PubMed ID: 7729900
[TBL] [Abstract][Full Text] [Related]
27. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
28. Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): requirements for GXM, APC activation, and interleukin-12.
Blackstock R; McElwee N; Neller E; Shaddix-White J
Infect Immun; 2000 Sep; 68(9):5146-53. PubMed ID: 10948138
[TBL] [Abstract][Full Text] [Related]
29. Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.
Nimrichter L; Frases S; Cinelli LP; Viana NB; Nakouzi A; Travassos LR; Casadevall A; Rodrigues ML
Eukaryot Cell; 2007 Aug; 6(8):1400-10. PubMed ID: 17573547
[TBL] [Abstract][Full Text] [Related]
30. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
[TBL] [Abstract][Full Text] [Related]
31. Regulated Release of Cryptococcal Polysaccharide Drives Virulence and Suppresses Immune Cell Infiltration into the Central Nervous System.
Denham ST; Verma S; Reynolds RC; Worne CL; Daugherty JM; Lane TE; Brown JCS
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203547
[No Abstract] [Full Text] [Related]
32. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
[TBL] [Abstract][Full Text] [Related]
33. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.
Chang ZL; Netski D; Thorkildson P; Kozel TR
Infect Immun; 2006 Jan; 74(1):144-51. PubMed ID: 16368967
[TBL] [Abstract][Full Text] [Related]
34. Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans.
Grijpstra J; Gerwig GJ; Wösten H; Kamerling JP; de Cock H
Eukaryot Cell; 2009 Aug; 8(8):1165-73. PubMed ID: 19542308
[TBL] [Abstract][Full Text] [Related]
35. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
36. O-acetylation of cryptococcal capsular glucuronoxylomannan is essential for interference with neutrophil migration.
Ellerbroek PM; Lefeber DJ; van Veghel R; Scharringa J; Brouwer E; Gerwig GJ; Janbon G; Hoepelman AI; Coenjaerts FE
J Immunol; 2004 Dec; 173(12):7513-20. PubMed ID: 15585878
[TBL] [Abstract][Full Text] [Related]
37.
Colombo AC; Rella A; Normile T; Joffe LS; Tavares PM; de S Araújo GR; Frases S; Orner EP; Farnoud AM; Fries BC; Sheridan B; Nimrichter L; Rodrigues ML; Del Poeta M
mBio; 2019 Apr; 10(2):. PubMed ID: 30940711
[No Abstract] [Full Text] [Related]
38. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.
Urai M; Kaneko Y; Ueno K; Okubo Y; Aizawa T; Fukazawa H; Sugita T; Ohno H; Shibuya K; Kinjo Y; Miyazaki Y
Front Cell Infect Microbiol; 2015; 5():101. PubMed ID: 26779451
[TBL] [Abstract][Full Text] [Related]
39. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
Deshaw M; Pirofski LA
Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565
[TBL] [Abstract][Full Text] [Related]
40. T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.
Sundstrom JB; Cherniak R
Infect Immun; 1993 Apr; 61(4):1340-5. PubMed ID: 8095924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
